Subscribe Become an Author Log In

BiopharmaTrend.com

Covering emerging technologies, innovations, and companies

Drug Discovery Insights


Next-Generation Sequencing Is The Next Big Thing In Pharmacogenomics

   by Ximena Rodriguez    317
Next-Generation Sequencing Is The Next Big Thing In Pharmacogenomics

Pharmacogenomics seeks to understand underlying genetic markers that influence treatment responses and modification of therapies to increase efficacy treatment success (Monte et al., 2012). This field has greatly benefited from classical approaches to identify polymorphisms and the molecular basis involved in drug interaction with targets their activity with treatments.

Next generation sequencing makes it possible to simultaneously study DNA polymorphisms across the genome, couple it with RNA analysis and the proteome comparably faster and cheaper. Ideal pharmacogenomic markers should be easily detectable and integratable into improving personalized medicine (Chauvin and Boisvert, 2018). Here we present some of these case studies and how information gleaned from DNA, protein and [RNA analysis] has helped improve our understanding of treatments and tailor medicine for specific case studies (personalized medicine).

Hunting Dark Genes For Druggable Targets

   by Tudor Oprea    333
Hunting Dark Genes For Druggable Targets

About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins are simply not well characterized (Figure 1).

There may be multiple reasons why dark genes are ignored, although the literature isn't always in agreement with data availability.

Are you curious where dark gene hunting leads? There are a number of resources:

"Hot" Research Areas in Drug Discovery - 2019

   by Andrii Buvailo    1883
"Hot" Research Areas in Drug Discovery - 2019

Things like gene editing, stem cells, immunotherapies and new types of biologics are now mega-trends in the pharmaceutical industry, widely covered in media, and I guess there is little doubt that biology is the next big thing in medicine. However, in this post I would like to outline several hot areas in small molecule drug discovery, suggesting a lot of untapped potential and investment prospects in this more “traditional” pharmaceutical research space.

Artificial Intelligence Yields Early Results in Drug Discovery

   by Andrii Buvailo    1684
Artificial Intelligence Yields Early Results in Drug Discovery

A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance targeting a novel pathway for the treatment of chronic obstructive pulmonary disease (COPD). The milestone is among first early successes in drug discovery associated with the recent adoption of novel machine learning/AI methods and workflows.

How Latest Drug Candidates Were Discovered? (Retrospective Review, 2016-2017)

   by Andrii Buvailo    2795
How Latest Drug Candidates Were Discovered? (Retrospective Review, 2016-2017)

Recently D.G.Brown and J.Boström of AstraZeneca published an insightful analysis, where they reviewed lead generation research strategies behind 66 small molecule clinical candidates published over 2016-2017 in Journal of Medicinal Chemistry.  

Below is a brief summary of some key statistics and ideas outlined in the work (I encourage reading the original paper, it contains a ton of valuable insights and a strong list of references).